Immunotherapy for advanced lung squamous cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests how well immunotherapy works as a first treatment for advanced lung squamous cell carcinoma, either alone or with chemotherapy. It aims to see if this approach can help patients who haven't had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced lung squamous cell carcinoma.
- You are starting immunotherapy as your first treatment, possibly with chemotherapy.
- You are between 18 and 80 years old.
- You have not received any previous treatment for cancer in your lungs or elsewhere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy and an anti-angiogenesis drug (rh-endostatin) for people with advanced or recurrent squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new drug (EVM14) combined with an existing immunotherapy called ivonescimab for people with advanced squamous lung cancer that has not been treated before. The goal is to see if the combination is safe and if it helps shrink tumors.
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
This trial tests whether starting immunotherapy can help people with newly diagnosed advanced or limited-spread non-small cell lung cancer that cannot be fully cured with standard local treatments. It may offer a new treatment approach when surgery or definitive chemoradiation isn’t a good option.
Hear when a new Squamous Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.